Related Experiment Videos
New antiepileptic drugs
1Department of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland, UK.
Bailliere'S Clinical Neurology
|December 1, 1996
Summary
Eight new antiepileptic drugs (AEDs) emerged in the 1990s, offering diverse mechanisms for epilepsy management. This review details their efficacy, pharmacokinetics, and interactions, assessing their potential role in clinical practice.
Area of Science:
- Pharmacology
- Neurology
- Drug Development
Background:
- The 1990s witnessed the introduction of eight novel antiepileptic drugs (AEDs).
- These AEDs feature diverse mechanisms of action, expanding therapeutic options for epilepsy.
- Established AEDs provided a baseline for comparison.
Purpose of the Study:
- To review new antiepileptic drugs (AEDs) introduced in the 1990s.
- To detail their mechanisms of action, pharmacokinetics, and adverse drug interactions.
- To assess their efficacy, tolerability, and practical use in epilepsy management.
Main Methods:
- Monographs were prepared for lamotrigine, vigabatrin, gabapentin, oxcarbazepine, felbamate, and topiramate.
- Information on efficacy, tolerability, pharmacokinetics, and interactions was compiled.
- Ongoing studies and potential future roles were identified.
Main Results:
- Detailed monographs cover seven specific AEDs, highlighting their unique properties.
- The review assesses the comparative advantages of new AEDs over established ones.
- Zonisamide and investigational drugs like remacemide, losigamone, and levetiracetam are also discussed.
Conclusions:
- New AEDs offer varied mechanisms and improved profiles for epilepsy treatment.
- Understanding their specific indications and interactions is crucial for optimal patient care.
- Further research and clinical trials will define the long-term place of these agents.